Methods and compositions employing 4-aminophenylacetic acid compounds
View Patent ↗The invention provides compositions comprising 4-APAA compounds and methods for treating disorders involving inflammation of the intestinal system, such as inflammatory bowel disease. The methods and compositions of the invention also include combinations of 4-APAA compounds and 5-ASA compounds for treatment of such disorders.
1. A pharmaceutical composition comprising:
a first therapeutic agent selected from the group consisting of:
azo-bonded 4-aminophenylacetic acid (4-APAA) compound;
non-azo bonded 4-APAA compound; and
azo-bonded 5-aminosalicylic acid (5-ASA) compound;
non-azo bonded 5-ASA compound; and
a second therapeutic agent comprising a
4-APAA compound azo bonded to a 5-ASA compound.
2. The pharmaceutical composition of claim 1 further comprising another therapeutic agent selected from the group consisting of: steroids, antibiotics, stool softeners, stool hardeners, nutraceuticals, probiotic agents and organisms, and nicotinic agents.
3. The pharmaceutical composition of claim 1 formulated to deliver the first therapeutic agent to the small intestine.
4. The pharmaceutical composition of claim 1 formulated to release the first therapeutic agents along the length of the small intestine and the second therapeutic agent along the length of colon.
5. The pharmaceutical composition of claim 1 formulated to release the second therapeutic agents along the length of the distal portion of the small intestine and the colon.
6. The pharmaceutical composition of claim 1 formulated to release the second therapeutic agents along the length of the colon.
7. The pharmaceutical composition of claim 1 formulated to pass through the stomach and to release the active agent in the intestine.
8. The pharmaceutical composition of claim 1 formulated as a suppository.
9. The pharmaceutical composition of claim 1 formulated for administration as an enema.
10. A pharmaceutical composition comprising at least
a first and second therapeutic agent, wherein the first therapeutic agent is formulated to release in the stomach or small intestine and selected from the group consisting of
azo-bonded 4-aminophenylacetic acid (4-APAA compound;
non-azo bonded 4-APAA compound;
azo-bonded 5-aminosalicylic acid (5-ASA) compound; and
non-azo bonded 5-ASA compound; and
wherein the second therapeutic agent is formulated to release in the distal portion of the small intestine or colon and selected from the group consisting of:
4-APAA compound azo bonded to a 5-ASA compound; and
a combination of 4-APAA compound and a 5-ASA compound.
11. The pharmaceutical composition of claim 10 wherein:
the first therapeutic agent is a 5-ASA compound formulated for release in the stomach and the second therapeutic agent is a 4-APAA compound azo bonded to a 5-ASA compound formulated for release in a distal portion of the small intestine.
12. The pharmaceutical composition of claim 10 wherein:
the first therapeutic agent is a 5-ASA compound formulated for release in the small intestine and the second therapeutic agent is a 4-APAA compound azo bonded to a 5-ASA compound formulated for release in the colon.
13. A method of treating an inflammatory colon condition comprising administering to a subject a pharmaceutical composition of claim 1 or 10 in an amount sufficient to reduce the inflammatory inflammatory colon condition.